Tamara Sobel, MD
Internal Medicine · Owings Mills, MDNPI 1194714857
Payments from drug & device makers
Across 341 payments — averaging $17.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$968
- Amgen$773
- Lilly USA, LLC$729
- Novo Nordisk$720
- Pfizer$421
- AstraZeneca$410
- plus $2K from 25 others
What the payments were for
- Food & beverage$5,947100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 68 | $968 |
| Amgen(2 entities) | 44 | $773 |
| Lilly USA, LLC | 43 | $729 |
| Novo Nordisk | 40 | $720 |
| Pfizer | 24 | $421 |
| AstraZeneca | 20 | $410 |
| GSK | 16 | $295 |
| Novartis | 14 | $261 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 9 | $158 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $112 |
| Biohaven Pharmaceutical Holding Company Ltd. | 6 | $111 |
| Sumitomo Pharma America, Inc. | 4 | $109 |
| Daiichi Sankyo Inc. | 5 | $107 |
| Idorsia Pharmaceuticals US Inc | 5 | $79 |
| Kowa Pharmaceuticals America, Inc. | 5 | $79 |
| Eisai Inc. | 4 | $77 |
| Merck | 4 | $74 |
| Exact Sciences | 3 | $63 |
| Astellas Pharma US Inc | 4 | $60 |
| Esperion Therapeutics, Inc. | 3 | $57 |
| E.r. Squibb & Sons, L.L.C. | 2 | $48 |
| Boston Scientific | 3 | $47 |
| Cleerly, Inc. | 1 | $35 |
| Sanofi | 2 | $29 |
| Bausch Health US, LLC | 1 | $24 |
| Kaleo, Inc. | 1 | $22 |
| Philips North America LLC | 1 | $21 |
| Abbott | 1 | $17 |
| Biohaven Pharmaceuticals, Inc. | 1 | $17 |
| Boehringer Ingelheim | 1 | $13 |
| Sanofi Pasteur Inc. | 1 | $13 |
How this compares
$5,947 in reported general payments places this provider in the 90th percentile of 2,979 internal medicine providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 97 | $89,029 |
| OzempicSemaglutide | 65 | $73,881 |
| MyrbetriqMirabegron | 27 | $28,156 |
| TrulicityDulaglutide | 11 | $25,266 |
| MounjaroTirzepatide | 19 | $17,254 |
| JardianceEmpagliflozin | 15 | $16,183 |
| EntrestoSacubitril/Valsartan | 13 | $14,638 |
| Repatha SureclickEvolocumab | 15 | $11,037 |
| Aimovig AutoinjectorErenumab-Aooe | 12 | $8,586 |
| GemtesaVibegron | 14 | $7,791 |
| SynthroidLevothyroxine Sodium | 55 | $5,107 |
| Dexlansoprazole DrDexlansoprazole | 12 | $4,034 |
| Ezetimibe | 116 | $3,205 |
| EdarbiAzilsartan Medoxomil | 12 | $2,941 |
| Celecoxib | 23 | $2,697 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $421 | $89,02997 claims |
| Novo NordiskOzempic | $720 | $73,88165 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $729 | $42,52030 claims |
| Astellas Pharma US IncMyrbetriq | $60 | $28,15627 claims |
| Boehringer IngelheimJardiance | $13 | $16,18315 claims |
| NovartisEntresto | $261 | $14,63813 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $109 | $7,79114 claims |
| AbbVieSynthroid | $968 | $5,10755 claims |
| GSKArnuity Ellipta | $295 | $2,38212 claims |
| Kowa Pharmaceuticals America, Inc.Bystolic | $79 | $2,18911 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,979 internal medicine providers in Maryland.
Other internal medicine in Owings Mills
- Shishir KhetanRockville$52.1M
- Steven GellerElkridge$15.1M
- Mary HowellHagerstown$6.2M
- Kristen MarroneBaltimore$5.6M
- Jonathan CohenRockville$5M
- Andrea ApoloBethesda$4.8M
- Peta-Gay Jackson BoothBaltimore$3.6M
- Rahul PatelRockville$2.8M
- Mark YarchoanBaltimore$2.4M
- Marianne MannHighland$2.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.